MS and Demyelinating Disorders

The drug's impact on neuroinflammation and neurodegeneration in the brain and spinal cord are currently being explored.

Five-year EXPAND study data suggest that Novartis’s S1P receptor modulator has sustained benefit and delays disability over long-term treatment in patients with SPMS.

The Group Medical Director of Neuroscience at Genentech discussed the shorter, 2-hour infusion time for ocrelizumab and how it might impact multiple sclerosis care as a whole.

Exclusive breastfeeding may be recommended after it was shown to reduce the risk of postpartum relapses.

The FDA has accepted an sBLA for a version of Genentech's ocrelizumab with a shorter administration time for the treatment of relapsing and primary progressive MS.

Neurology News Network for the week ending April 18, 2020.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending April 17, 2020.

In those with secondary progressive MS, evaluating diffusely abnormal white matter may provide a useful measure for therapies aiming to protect at-risk tissue, which may be able to slow progression.

The Processing Speed Test, a tech-enabled version of the SDMT, was shown to be significantly correlated with multiple measures in routine multiple sclerosis care.

The director of the Multiple Sclerosis Program at Cleveland Clinic Lou Ruvo Center for Brain Health discussed the correlation between age and disease duration in MS, as well as what was learned from a subanalysis of the EXPAND study of siponimod.

The probability of relapse and disability progression during pregnancy was associated with time when natalizumab was stopped and number of relapses in the year before natalizumab treatment.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending April 10, 2020.

The COViMs website includes FAQs, a sample Case Report Form, and COVID-19 esources and will provide real-time data on patients with multiple sclerosis and other central nervous system demyeliminating diseases who have developed COVID-19.

As the treatment of multiple sclerosis continues to evolve and improve, the proposition of lifetime therapy has come under scrutiny.

The director of the MS Comprehensive Care Center at Stony Brook University discussed the need for more innovative approaches to DMTs and better communication about disease processes from physicians.

Disease-modifying therapies used to treat several immune-mediated disorders in neurology may make patients more susceptible to the novel coronavirus.

The North American Registry for Care and Research in MS reached a major milestone, enrolling its 750 patient in an effort to understand more about the disease course of multiple sclerosis.

Both the Plegridy and Avonex drug labels no longer contain the "Pregnancy Category C" classification with the report of human pregnancy registry data.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending April 3, 2020.

The director of the MS Comprehensive Care Center and interim chair of the department of neurology at Stony Brook University spoke to the importance of properly communicating with patients with MS as a physician.

The director of Pediatric MS and Wellness programming at the Mellen Center and assistant professor of neurology at Cleveland Clinic Lerner College of Medicine discussed the harsh realities of patients adopting a new treatment method.

Mayo Clinic is in the forefront of changing practice techniques during the COVID-19 pandemic by using video appointments to reach patients.

NeurologyLive’s parent company, MJH Life Sciences, will be hosting the virtual MJH Life Sciences Sleeves Up Blood Drive from March 31 through April 30.

The director of the MS Comprehensive Care Center and interim chair of the department of neurology at Stony Brook University spoke to the debates around halting and beginning treatment in patients with MS.

The director of the MS Comprehensive Care Center and interim chair of the department of neurology at Stony Brook University discussed the need for more originality in the MS pipeline.